Asset Impairment Testing for Pre-IPO Companies: Assessing the Recoverable Amount of Long-Lived Assets

The SFC’s 2024-25 enforcement priorities, published in its Annual Report in June 2024, explicitly flagged “aggressive revenue recognition and asset valuation” as a key focus for IPO vetting. This directive, combined with the HKEX’s 2023 guidance on listing applicants with material goodwill (HKEX-GL112-23), means that a pre-IPO company’s approach to asset impairment testing is no longer a mere accounting compliance exercise—it is a material disclosure risk that can delay or derail a listing application. For CFOs preparing a Form A1, the recoverable amount of long-lived assets—property, plant, equipment (PPE), intangible assets, and goodwill—must withstand scrutiny from both the reporting accountant and the Listing Division. The 2024 market correction in Chinese equities, which saw the Hang Seng Index decline 13.7% year-to-date by 31 December 2024, has further compressed valuation multiples across sectors, making impairment triggers more likely. This article dissects the regulatory framework, the mechanics of recoverable amount assessment under HKAS 36, and the specific audit and disclosure expectations for pre-IPO companies in Hong Kong.

The Regulatory Framework for Impairment Testing in a Listing Context

The primary accounting standard governing asset impairment in Hong Kong is HKAS 36 Impairment of Assets, which is substantively converged with IAS 36. For pre-IPO companies, the standard interacts directly with the HKEX Listing Rules, specifically Main Board Rule 9.11(23a), which requires the reporting accountant to opine on the company’s financial position, including the adequacy of impairment provisions. The SFC’s Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission (Chapter 571, subsidiary legislation) further imposes a duty on sponsors to ensure that the listing applicant’s financial statements are not misleading, which includes verifying the reasonableness of impairment assumptions.

The Trigger: Identifying Indicators of Impairment

Under HKAS 36.12, an entity must assess at each reporting date whether there is any indication that an asset may be impaired. For pre-IPO companies, the most common impairment indicators arise from external sources: a significant decline in market value (HKAS 36.12(a)), adverse changes in the technological, market, economic, or legal environment (HKAS 36.12(b)), and increases in market interest rates (HKAS 36.12(c)). The 2024-2025 interest rate environment, with the HIBOR 3-month rate averaging 4.25% in Q4 2024 (HKMA Monthly Statistical Bulletin, January 2025), represents a material increase compared to the 1.50% average in Q4 2022, directly affecting the discount rates used in value-in-use calculations.

Internal indicators include evidence of obsolescence or physical damage (HKAS 36.12(d)), and a current period operating loss combined with a history of past losses (HKAS 36.12(f)). A pre-IPO company that has reported a net loss in its latest financial year must document why this does not constitute an impairment trigger, or if it does, the basis for the recoverable amount calculation.

The Unit of Account: Cash-Generating Units (CGUs) and Goodwill

Impairment testing is not performed on individual assets if they do not generate cash inflows that are largely independent of other assets. HKAS 36.66 requires that goodwill acquired in a business combination be allocated to each of the acquirer’s cash-generating units (CGUs) expected to benefit from the synergies of the combination. For a pre-IPO company that has grown through acquisitions—common in the technology and healthcare sectors—the identification of CGUs is a critical judgment area.

The HKEX’s guidance in Listing Decision HKEX-GL112-23 (December 2023) specifically addresses pre-IPO companies with significant goodwill. The exchange expects that the allocation of goodwill to CGUs is consistent with the way management monitors and makes decisions about the business. If the CGU is defined at too high a level (e.g., the entire company), the impairment test may mask a failing segment. Conversely, if defined at too granular a level, it may trigger unnecessary impairment charges. The SFC’s Report on the Inspection of Listing Applicants’ Financial Statements (2023) noted that in 40% of the cases reviewed, the identification of CGUs was inconsistent with the internal management reporting structure, a red flag for the Listing Division.

Recoverable Amount: Fair Value Less Costs of Disposal vs. Value in Use

HKAS 36.18 defines recoverable amount as the higher of an asset’s or CGU’s fair value less costs of disposal (FVLCD) and its value in use (VIU). For pre-IPO companies, the choice between these two measures—and the assumptions underpinning each—is the most contested area during the sponsor’s due diligence and the reporting accountant’s audit.

Fair Value Less Costs of Disposal (FVLCD)

FVLCD is measured in accordance with HKFRS 13 Fair Value Measurement. For a pre-IPO company, the most reliable evidence of fair value is a binding sale agreement in an arm’s-length transaction (Level 1 input). In practice, this is rare for long-lived assets. More commonly, companies use a market approach (comparable transactions or multiples) or an income approach (discounted cash flows of the asset itself, if separable).

The SFC has scrutinised FVLCD assumptions in several enforcement cases. In SFC v. Asia Coal Ltd (2022, HCCT 45/2020), the court found that the company had used an unsupported market multiple of 8x EBITDA for a coal mine, when the prevailing industry multiple was 4.5x to 5.5x. The overvaluation led to a material understatement of an impairment loss of HKD 480 million. For pre-IPO companies, the sponsor must ensure that any comparable transaction analysis includes adjustments for size, growth, risk, and market conditions. The discount rate used in an income approach for FVLCD should reflect the asset-specific risk, not the company’s weighted average cost of capital (WACC).

Value in Use (VIU)

VIU is the present value of the future cash flows expected to be derived from an asset or CGU. HKAS 36.30 requires that cash flow projections be based on the most recent financial budgets/forecasts approved by management, covering a maximum period of five years (unless a longer period can be justified). For a pre-IPO company, the key assumptions are:

• Growth rate: The terminal growth rate must not exceed the long-term average growth rate for the products, industries, or country in which the entity operates (HKAS 36.33(c)). For a Hong Kong-based company, a terminal growth rate exceeding 3.0% (the long-term nominal GDP growth rate for Hong Kong, per the Census and Statistics Department, 2024) would require exceptional justification.
• Discount rate: The pre-tax discount rate must reflect the time value of money and the risks specific to the asset for which the future cash flow estimates have not been adjusted (HKAS 36.55). The SFC’s 2023 inspection report noted that 35% of reviewed applicants used a post-tax discount rate and then applied it to pre-tax cash flows, a fundamental error that overstates the recoverable amount.
• Capital expenditure: The projections should include the capital expenditure necessary to maintain the asset’s current operating capacity. A pre-IPO company that projects high revenue growth without corresponding capex for maintenance is presenting an unrealistic VIU.

Audit and Disclosure Expectations for the Reporting Accountant

The reporting accountant’s work on impairment testing is governed by Hong Kong Standards on Auditing (HKSA) 540 Auditing Accounting Estimates and Related Disclosures, and HKSA 570 Going Concern. For a pre-IPO engagement, the reporting accountant must perform procedures that are more detailed than a standard statutory audit, given the heightened public interest and the SFC’s focus on IPO financials.

Sensitivity Analysis and the “Reasonably Possible Change” Test

HKAS 36.134(f) requires disclosure of the sensitivity of the recoverable amount to changes in key assumptions, if a reasonably possible change would cause the carrying amount to exceed the recoverable amount. The SFC’s Guidance Note on Financial Reporting for Listing Applicants (2022, revised) explicitly states that the reporting accountant should verify that management has performed this sensitivity analysis and that the disclosure is included in the prospectus.

For example, if a pre-IPO company’s CGU has a carrying amount of HKD 1.2 billion and a recoverable amount of HKD 1.3 billion, a 10% reduction in the terminal growth rate (from 3.0% to 2.7%) or a 50 bps increase in the discount rate (from 10.0% to 10.5%) could wipe out the headroom. The prospectus must disclose these thresholds, and the sponsor must confirm that the assumptions are supportable.

Impairment Reversals and the Listing Timeline

Under HKAS 36.124, an impairment loss recognised for goodwill cannot be reversed in subsequent periods. For other assets, reversals are permitted only if there has been a change in the estimates used to determine the recoverable amount (HKAS 36.114). For a pre-IPO company, the reporting accountant must be alert to the temptation to reverse prior impairment losses in the period immediately before listing to inflate earnings. The SFC’s Enforcement Bulletin (Issue 4, 2023) highlighted a case where a company reversed a HKD 200 million impairment on a property right before listing, citing a change in market conditions. The SFC found that the “change” was a single unsupported valuation report, and the company was required to restate its financials, delaying the listing by six months.

Disclosure in the Accountants’ Report and Prospectus

The accountants’ report, which forms part of the prospectus under Main Board Rule 11.10, must include a breakdown of the carrying amount of each class of impaired assets, the impairment loss recognised or reversed, and the basis for determining the recoverable amount (FVLCD or VIU). The HKEX’s Guidance Letter GL55-13 (November 2013, updated 2023) requires that the prospectus include a separate risk factor section on asset impairment, particularly if the company has significant goodwill or intangible assets.

For a pre-IPO company with a December year-end, the track record period typically covers three full financial years. If an impairment event occurs in the stub period (e.g., between the last audited year-end and the date of the prospectus), the sponsor must ensure that the interim financial information reflects the impairment, or that a subsequent event disclosure is made. The SFC’s Code of Conduct (paragraph 17.6) requires the sponsor to update the Listing Division on any material adverse change, including impairment.

Practical Considerations for Pre-IPO CFOs and SPV Designers

The impairment testing process for a pre-IPO company is not a once-a-year exercise. It must be embedded into the financial reporting cycle from the start of the track record period. The following are specific, actionable steps that CFOs and their advisors should take.

Structuring the CGU Map Before the Acquisition

For a company that plans to grow through acquisitions before listing, the allocation of goodwill to CGUs should be decided at the time of the acquisition, not during the impairment test. The CGU map should mirror the internal management reporting structure, as required by HKAS 36.80. If the company operates in different jurisdictions (e.g., a PRC parent with a BVI intermediate holding company and a Hong Kong operating subsidiary), the CGU should be defined at the level where the cash flows are generated. A common error is to allocate goodwill to the BVI holding company, which has no operating cash flows, and then test for impairment at the consolidated level only.

Using External Valuers and Documentation

While HKAS 36 does not mandate the use of an external valuer, the SFC’s Guidance Note on Financial Reporting recommends that for significant CGUs (those where the carrying amount exceeds 10% of total assets), the reporting accountant should consider engaging an independent valuer to corroborate the discount rate and the terminal growth rate. The valuation report should be prepared in accordance with the Hong Kong Institute of Surveyors Valuation Standards (2024 edition) for property-related assets, or the International Valuation Standards for other assets.

The documentation should include a clear audit trail for each assumption: the source of the market data, the calculation of the discount rate (including the risk-free rate, equity risk premium, and company-specific risk premium), and the basis for the growth rates. The SFC’s 2023 inspection report found that 60% of the reviewed applicants had inadequate documentation for their discount rate assumptions, with many simply using a WACC from a competitor without adjustment.

Stress-Testing the Listing Valuation

The pre-IPO valuation implied by the last funding round (e.g., a Series C or D round) is often used as a starting point for the FVLCD calculation. However, the sponsor must ensure that the valuation is arm’s-length and not based on a round with preferential liquidation rights or other terms that inflate the headline valuation. The SFC’s Statement of Policy on Pre-IPO Investments (2022) requires that any pre-IPO investment with a valuation above the IPO price be disclosed and explained. If the pre-IPO valuation is not supportable, the carrying amount of the CGU may be overstated, triggering an impairment charge that reduces the IPO proceeds.

Closing Takeaways

The following are specific, actionable conclusions for CFOs and advisors preparing for a Hong Kong listing.

1. Map CGUs to internal management reporting before any acquisition to ensure goodwill allocation is consistent with HKAS 36.80 and the HKEX’s GL112-23 guidance; a mismatch is a common SFC inspection finding.
2. Use a pre-tax discount rate for VIU calculations and document the build-up from the risk-free rate (Hong Kong Exchange Fund Notes 10-year yield, currently 3.82% as of 31 January 2025) through the equity risk premium and company-specific risk premium.
3. Perform a sensitivity analysis for each CGU with headroom of less than 20% and disclose the reasonably possible change thresholds in the prospectus risk factors.
4. Engage an independent valuer for any CGU exceeding 10% of total assets and ensure the valuation report follows the HKIS or IVS standards.
5. Do not reverse a prior impairment loss within 12 months of the listing date without a clear, documented change in external market conditions; the SFC will scrutinise any reversal that inflates the track record earnings.